摘要
本文测定了１２例高血压病患者经伊拉地平（Ｉｓｒａｄｉｐｉｎｅ）（１．２５ｍｇ～２．５ｍｇ，１日２次）治疗８周前后和１０例健康对照者的血小板聚集性（ＰＡｇ）、血浆组织型纤溶酶原激活剂（ｔ－ＰＡ）及其抑制物（ＰＡＩ）活性。结果表明，高血压组ＰＡｇ、ＰＡＩ活性明显高于对照组，ｔ－ｐＡ活性显著低于对照组；伊拉地平治疗后，ＰＡｇ、ＰＡＩ活性显著降低，ｔ－ＰＡ活性显著升高。本文提示：高血压病患者存在血小板功能亢进和纤溶活性降低，伊拉地平能够抑制血小板聚集，增强纤溶活性，在防治心脑血管并发症方面具有重要意义。
In order to study the influence of isradipine on platelet function and fibrinolytic activity,twelve patients with mild to moderate essential hypertension were compared, after 2 weeks of placebo,with an ageand sex-matched group of 12 healthy volunteers for platelet aggregation in response to adenosine diphosphate(ADP),tissue plasminogen activator(t-PA) and plasminogen activator inhibitor(PAI) activity in plasma.The effect of calcium antagonist isradipine,1.25-2.5 mg twice daily,on platelet aggregation,t-PA and PAI activity was measured after 8 weeks of treatment.Platelet aggregation and PAI activity were significantly increased in the hypertensives as compared with controls.t-PA activity was significantly reduced,while tPA activity was significantly increased.
出处
《中国循环杂志》
CSCD
1994年第5期267-269,共3页
Chinese Circulation Journal
关键词
高血压
血小板功能
纤溶活性
Hypertension
Isradipine
Calcium antagonist
Platelet function
Tissue plasminogen activator and inhibitor
